Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder

Journal of Substance Abuse Treatment

Volumn 38, Issue 4, 2010, Pages 384-393

  Williams, Jill M ^a,b   Steinberg, Marc L ^a,b   Zimmermann, Mia Hanos ^a   Gandhi, Kunal K ^a,b   Stipelman, Brooke ^c   Budsock, Patricia Dooley ^a   Ziedonis, Douglas M ^d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UMDNJ School of Public Health   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Behavioral therapy; Mental illness; Nicotine; Randomized clinical trial; Smoking cessation

Indexed keywords

CARBON MONOXIDE; NICOTINE;

ADULT; ARTICLE; ATTITUDE TO HEALTH; BEHAVIOR THERAPY; CIGARETTE SMOKING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; MOTIVATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADMINISTRATION, CUTANEOUS; ADULT; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; DIRECTIVE COUNSELING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PSYCHOTIC DISORDERS; RECURRENCE; SCHIZOPHRENIA; SMOKING CESSATION; TIME FACTORS; TOBACCO USE DISORDER;

EID: 77952238720     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.03.006     Document Type: Article

References (42)

1. Addington J., el-Guebaly N., Campbell W., Hodgins D.C., Addington D. Smoking cessation treatment for patients with schizophrenia. American Journal of Psychiatry 1998, 155:974-976.
2. Baker A., Richmond R., Haile M., Lewin T.J., Carr V.J., Taylor RL, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. American Journal of Psychiatry 2006, 163:1934.
3. Beck A.T., Ward C.H., Mendelson M. An inventory for measuring depression. Archives of General Psychiatry 1961, 4:461-471.
4. Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 2000, 177:212-217.
5. Covey L.S., Hughes D., Glassman A.H., Blazer D., George L.K. Ever-smoking, quitting, and psychiatric disorders: Evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tobacco Control 1994, 3:222-227.
6. Dalack G.W., Healy D.J., Meador-Woodruff J.H. Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. American Journal of Psychiatry 1998, 155:1490-1501.
7. de Leon J., Diaz F. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and smoking behaviors. Schizophrenia Research 2005, 76:135-157.
8. Evins A.E., Cather C., Rigotti N.A., Freudenreich O., Henderson D.C., Olm-Shipman C.M., et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: Increased rates of smoking cessation and reduction. Journal of Clinical Psychiatry 2004, 65:307-311.
9. Fagerström K.O., Hughes J.R. Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: A review. Nicotine and Tobacco Research 2002, 4(Suppl 2):S73-S79.
10. Fagerström K.O., Tejding R., Westin A., Lunell E. Aiding reduction of smoking with nicotine replacement medications: Hope for the recalcitrant smoker?. Tobacco Control 1997, 6:311-316.
11. Fiore M.C., Jaén C.R., Baker T.B., Bailey W.C., Benowitz N.L., Curry S., et al. Treating tobacco use and dependence: 2008 update. clinical practice guideline 2008, U.S. Department of Health and Human Services. Public Health Service, Rockville, MD.
12. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12:189-198.
13. George T.P., Vessicchio J.C., Sacco K.A., Weinberger A.H., Dudas M.M., Allen T.M., et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biological Psychiatry 2008, 63:1092-1096.
14. George T.P., Vessicchio J.C., Termine A., Bregartner T.A., Feingold A., Rounsaville B.J., et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry 2002, 52:53-61.
15. George T., Ziedonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry 2000, 157:1835-1842.
16. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 2005, 80:45-53.
17. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction 1991, 86:1119-1127.
18. Hitsman B., Moss T.G., Montoya I.D., George T.P. Treatment of tobacco dependence in mental health and addictive disorders. Canadian Journal of Psychiatry 2009, 54:368-378.
19. Horvath A.O., Greenberg L. Development and validation of the Working Alliance Inventory. Journal of Counseling Psychology 1989, 36:223-233.
20. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry 1986, 143:993-997.
21. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. British Journal of Psychiatry 1989, 7:59-67.
22. Kleber H.D., Weiss R.D., Anton R.F., Rounsaville B.J., George T.P., Strain E.C., et al. American Psychiatric Association, treatment of patients with substance use disorders, second edition. American Journal Psychiatry 2006, 163(8 Suppl):5-82.
23. Lasser K., Wesley B.J., Woolhandler S., Himmestein D.U., McCormick D., Bor D.H. Smoking and mental illness: A population-based prevalence study. Journal of the American Medical Association 2000, 284:2606-2610.
24. Leslie D.L., Rosenheck R.A. Benchmarking the quality of schizophrenia pharmacotherapy: A comparison of the Department of Veterans Affairs and the private sector. Journal of Mental Health Policy and Economics 2003, 6:113-121.
25. McChargue D.E., Gulliver S.B., Hitsman B. Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment?. Addiction 2002, 97:785-793.
26. McLellan A.T., Luborsky L., Woody G.E., O ' Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous and Mental Disease 1980, 168:26-33.
27. Montoya I., Vocci F. Medications development of the treatment of nicotine dependence in individuals with schizophrenia. Journal of Dual Diagnosis 2007, 3:113-150.
28. Sobell L.C., Sobell M.B. Alcohol Timeline Followback (TLFB) user's manual 1996, Addiction Research Foundation, Toronto, Canada.
29. Spitzer, R. L., & Williams, J. B. W. (1985). Structured Clinical Interview for DSM-III-R. New York: Biometrics Research Department, New York State Psychiatric Institute.
30. Steinberg M.L., Williams J.M. Psychosocial treatments for individuals with schizophrenia and tobacco dependence. Journal of Dual Diagnosis 2007, 3:99-112.
31. Steinberg M.L., Williams J.M., Ziedonis D.M. Financial implications of cigarette smoking among individuals with schizophrenia. Tobacco Control 2004, 13:206.
32. Steinberg M.L., Ziedonis D.M., Krejci J.A., Brandon T.H. Motivational interviewing with personalized feedback: A brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. Journal of Consulting and Clinical Psychology 2004, 72:723-728.
33. Strand J., Nybäck H. Tobacco use in schizophrenia: A study of cotinine concentrations in the saliva of patients and controls. European Psychiatry 2005, 20:50-54.
34. Stout R.L., Wirtz P.W., Carbonari J.P., DelBoca F.K. Ensuring balanced distribution of prognostic factors in treatment outcome research. Journal of Studies on Alcohol 1994, 12:70-75.
35. Williams J.M., Gandhi K.K., Foulds J., Steinberg M.B., Lu S.E., Masumova F., et al. No advantage for high dose compared to regular dose nicotine patch on short-term abstinence rates in schizophrenia 2007, Austin, TX.
36. Williams J.M., Gandhi K.K., Steinberg M.L., Foulds J., Ziedonis D.M., Benowitz N. Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia. Nicotine and Tobacco Research 2007, 9:873-881.
37. Williams J.M., Ziedonis D.M., Abanyie F., Steinberg M.L., Foulds J., Benowitz N. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophrenia Research 2005, 79:323-335.
38. Ziedonis D.M., George T.P. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and of neurobiological and clinical issues. Schizophrenia Bulletin 1997, 23:247-254.
39. Ziedonis D., Hitsman B., Beckham J.C., Zvolensky M., Adler L.E., Audrain-McGovern J., et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine and Tobacco Research 2008, 10:1691-1715.
40. Ziedonis D.M., Kosten T.R., Glazer W.M., Frances R.J. Nicotine dependence and schizophrenia. Hospital and Community Psychiatry 1994, 45:204-206.
41. Ziedonis D.M., Stern R. Dual recovery therapy for schizophrenia and substance abuse. Psychiatric Annals 2001, 31:255-264.
42. Ziedonis D.M, Trudeau K. Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model. Schizophrenia Bulletin 1997, 23:229-238.